6550-- Ventena Contract Request

Active

Contract Opportunity

Special Notice Notice of Intent to Award a Sole Source Procurement

The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract to Roche Diagnostics Corporation for procurement of the following reagents and consumable supplies:

Estimated Annual Quantities

Item Description
Item Number
Quantity
1
Reagent, DAB Detection
760-500
25
2
Reagent, Stainer, Amplification
760-080
20
3
Reagent, Stainer, Reaction Buffer
950-300
40
4
Reagent, Hematoxylin
760-2021
26
5
Reagent, Bluing Agent
760-2037
26
6
Staining Solution, Protease
760-2018
7
7
10x EZ Stainer, Prep Solution, 2L
950-102
15
8
Benchmark Ultra LCS
650-210
80
9
Solution, Ultra, Cell CC1
950-224
14
10
Control, Negative Monoclonal
760-2014
6
11
Elastin Van Gieson Kit 50 Test
Cat. 09592229001
6
12
Staining Kit, Complex Stains, Reticulum II
860-024
4
13
Staining Kit, Complex Stains, Special
860-028
4
14
DEPAR Solution, BMK Special Stains
860-036
6
15
Liquid Coverslip, BMK Special Stains
860-034
10
16
Benchmark Special Stains Wash II
Catalog 08309817001
8
17
Benchmark Special Stains I Cleaning Kit
860-049
7
18
Ventana H. Pylori (SP48) PAB
790-1014
24
19
CONFIRM ANTI-THRYOID TRANSCRIPTION FACT

790-4398
8
20
Ribbon, Ebar Printer
1632900
3
21
Kit Pack Ebar
1418702
5
22
Confirm Cytokeratin7 Rabbitmono
790-4462
8
23
Antibody KI 67 (30-9) Rabbit Monoclonal
790-4286
8
24
S IHC ANTIBODY ROUTINE: CONFIRM ANTI-S100 (POLYCLONAL) PAB
760-2523
6
25
CONFIRM CYTOKERATIN 20 RABBIT MONO
790-4554
10
26
CONFIRM CYTOKERATIN 20 RABBIT MONO

790-4431
6
27
ANTI-CHROMOGRANIN A (LK2H10) PAB
760-2519
4
28
CONFIRM CYTOKERATIN 20 RABBIT MONO
790-7061
4
29
CD-138 (B-A38) PAB, CELL MARQUE
790-4248
4
30
CONFIRM ANTI-CD34 (QBEND/10) PRIMARY ANTIBODY
790-2927
4
31
CONFIRM ANTI-CD3 (2GV6) RABBIT MONOCLONAL

790-4341
4
32
CONFIRM ANTI-CD5 (SP19) RABBIT MONO

790-4451
4
33
CONFIRM ANTI-CD20 (L26) PAB

760-2531
4
34
CD68 (SP251V18) RABBIT MONOCLONAL AB

790-7248
4
35
VENTANA ANTI-CD10 (SP67)

790-4506
4
36
CONFIRM ANTI-SYNAPTOPHYSIN (SP11) RABBIT

790-4407
4
37
CYTOKERATIN (CAM 5.2) PAB
790-4555
4
38
IHC ANCILLARY, HEMATOXYLIN II

790-2208
2
39
IHC ANCILLARIES, OPTIVIEW AMPLIFICATION KIT

760-099
2
40
IHC ANCILLARIES: OPTIVIEW DAB DETECTION
KIT (250)

760-700
2

The requested items will be used on the Ventana BenchMark Ultra system. The requesting activity states that the government owns and operates a Ventana BenchMark Ultra System and that the requested reagents and consumable supplies are the only supplies compatible with the instrument. A sole source letter from Roche states that all Ventana detection reagents, ancillaries, antibodies and probes are developed and validated for exclusive use on the fully automated Ventana Benchmark IHC/ISH slide staining system and cannot be substituted. The proposed order will be considered a standing order; where, the supplies will be ordered throughout the period of performance, on an as-needed basis. Network Contracting Office 17 will request the acquisition of these supplies from Roche on an IDIQ contract with a five-year ordering period.

This notice is not to be considered a request for quotations or proposals. A contract will not be awarded based on an offer received in response to this notice; however, all responsible sources may submit a capability statement, proposal or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 5 days from the publication of this notice, a contract/order will be issued to Roche Diagnostics Corporation without any further notice.

The proposed contract actions are for supplies, which the government intends to negotiate with only one source. The anticipated statutory authorities permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements.

The proposed sole source procurement will be made by an open market pricing agreement with Roche Diagnostics Corporation.

Attachments/Links